August 30, 2024 8:07am

Waiting for the month to end, time to be off the rollercoaster

News: Alnylam Pharmaceuticals (ALNY -$32.45 or -11.31%) announced detailed results from the HELIOS-B P3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events by 28%, with similar reductions in both the mortality and cardiovascular events components of the endpoint,

The Commerce Department reported the (PCE) personal consumption expenditures price index rose 0.2%. Excluding volatile food and energy prices, core PCE also increased 0.2% for the month but was up 2.6% from a year ago. The 12-month figure was slightly softer than the 2.7% estimate. Personal income increased 0.3%, slightly higher than the 0.2% estimate, while consumer spending rose 0.5%, in line with the forecast. Core prices less housing increased just 0.1% on the month. As other inflation components ease, shelter has proven to be stubborn, again rising 0.4% in July, according to today’s report.

There is no breadline for share pricing and fact-based intelligence! A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations.

Never leave an investor uninformed 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Friday: The pre-open Dow futures are UP +0.20% or (+83 points), the S&P futures are UP +0.36% or (+20 points) and the Nasdaq futures are UP +0.65% or (+126 points)

  • Stock futures climbed Friday as investors prepared for a crucial inflation reading that’s closely eyed by the Fed,
  • European markets were higher,
  • Asia markets climb after U.S. data calms recession fears.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday: The Dow closed UP +243.63 points or +0.59%, the S&P closed DOWN -0.22 points or -0.00% while the Nasdaq closed DOWN -39.60 points or -0.23%

The July personal consumption expenditures index (PCE) index and the Fed's favored measure, the core PCE index, should rise 0.2% vs. June. PCE inflation should hold at 2.5% vs. a year earlier while core PCE inflation edges up to 2.7%.

  • Markets have paid close attention to the PCE data for several months, but the stakes are lower now after Fed chief Powell made it clear on Aug. 23 that policymakers will start cutting rates. <IBD>

 

Economic Data Docket:  

  • 8:30 am               Personal income (nominal)          
  • 8:30 am               Personal spending (nominal)       
  • 8:30 am               PCE index July                      
  • 8:30 am               PCE (year-over-year)                                     
  • 8:30 am               Core PCE index   July                      
  • 8:30 am               Core PCE (year-over-year)                                          
  • 9:45 am               Chicago Business Barometer (PMI)           
  • 10:00 am             Consumer sentiment (final)         

 

Thursday’s RegMed Investors (RMi) Closing bell: “regaining the urges to deliver the upside. Investors are happy with the upside, however what does it do and for expectation? As share pricing disappointment comes in alternating or leapfrogging sessions.” …  https://www.regmedinvestors.com/articles/13595

 

Q3/24:

  • August – I neutral, 9 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” looking toward… PCE data … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

The BOTTOM LINE:   Thursday, the stock market rally had a broad-solid advance for much of Thursday's action, but turned mixed … although the cell and gene therapy sector ascended …?? … with “uncle algo and his electronic trading dwarfs” drafted the winning session.

  • The Nasdaq, which reclaimed its 50-day line intraday, closed just above its 21-day.
  • I’d be WATING a week post conferences  to SELL a few sector equities up and then take some gains!

 

The last working session of summer is today, I’ve been enjoying a week of doing some hard labor to keep prospective.

 

Q3 and August’s 4th week and final day of month:

  • Thursday’s advance/decline line ended with a positive close of 25 incliner, 7 decliners and 3 flats
  • Wednesday ended with a negative close of 10 incliner, 23 decliners and 2 flats
  • Tuesday ended with a negative close of 8 incliners, 22 decliners and 5 flats
  • (8/26) Monday with a positive close of 18 incliners, 13 decliners and 4 flats
  • Friday ended with a positive close of 28 incliner, 5 decliners and 2 flats

 

A quote to ponder, “the economy is "not out of the woods yet" regarding a recession. While the economy is slowing, the labor market is cooling, inflation is trending downward, and the Federal Reserve is expected to cut rates, the implications for individuals "depends on the phase of life you're in." < Providence Financial & Insurance Services President Anthony Saccaro>

 

I STILL advise investing in revenue driven, collaborative partnered and solid runway funded companies like

  • Alnylam Pharmaceuticals (ALNY),
  • CRISPR Therapeutics (CRSP),
  • Lenz Therapeutics (LENZ),
  • Ionis Pharmaceuticals (IONS) and
  • Vericel (VCEL)

… calling out the few 2027 runways.

 

Think a game of monopoly and follow RMi’s interchanges to gain profit moves or recoup losses – eat the popcorn and ponder ANY moves!

  • Short on words, long on being Judicious!

 

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-military officer, x-FBI,  x-corporate manager and officer, an adjunct business school (MBA) professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and just about … everything!

  • As a quantamental “plotter” I equate myself to a quantitative analyst straddling fundamental stock picking to produce better results for investors. the term “quantamental,” blends the two styles setting forth my difference retail, trading and multiple investor categories.

TRUST but, VERIFY!

 

Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts to filter out or lessen the noise of back-and-forth share pricing from the sector rotation.

  • The short-term moving averages help you identify the momentum of the trend — that is, overbought or oversold

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.